PPARG and Parkinson disease: There is also growing evidence that PPARγ agonists have anti-oxidant effects (Nicolakakis et al., 2008; Xiong et al., 2008; Jung et al., 2007) and PD pathogenesis also involves oxidative stress (Jenner, 2003).